Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (>28 days and

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2022-02, Vol.6 (3), p.1004-1014
Hauptverfasser: Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoit, Rössig, Claudia, Kormany, William N., Viswagnachar, Puneeth, Chen-Santel, Christiane
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Bispecific - adverse effects
Antigens, CD19
CD3 Complex
Child
Clinical Trials and Observations
Humans
Lymphoma, B-Cell
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (>28 days and
ISSN:2473-9529
2473-9537
2473-9537
DOI:10.1182/bloodadvances.2021005579